For the Inventor, By the Inventor

Enter assignee name

Mitsubishi Tanabe Pharma Corporation

USPTO Granted Patents = 257

CIPO Patents = 123

EPO Patents = 183

Trademarks = 30

Forward Citations = 645

Loading Chart...

Loading Chart...

737 inventors (with patents filed for the assignee):

Takayuki Kawaguchi (17 out of 43 patents)

Mourad Saady (15 out of 44 patents)

Alistair Lochead (15 out of 75 patents)

4. Philippe Yaiche (15 out of 43 patents)

5. Toru Iijima (14 out of 15 patents)

6. Sumihiro Nomura (14 out of 29 patents)

7. Kazutoshi Watanabe (12 out of 75 patents)

8. Maiko Hamada (12 out of 12 patents)

9. Hidenori Akatsuka (12 out of 12 patents)

10. Kenji Fukunaga (9 out of 18 patents)

11. Norimitsu Hayashi (9 out of 9 patents)

12. Eiji Kawanishi (8 out of 8 patents)

13. Osamu Sakurai (8 out of 8 patents)

14. Hiroshi Sugama (8 out of 8 patents)

15. Fumihiko Akahoshi (8 out of 10 patents)

Core Competencies:

Edaravone

Amyotrophic Lateral Sclerosis

BRD4 Protein Degradation

Optically Active Pyrrolidine

IL-33 Antagonist

Syndecan-1 Binding Agents

Nucleic Acid ALNA

Monoclonal Antibodies

Vasomotor Symptoms Treatment

Cocaine Addiction Treatment

Heterocyclic Compounds

257 patents: Sort by Forward Citations

1. 12478611 - Pharmaceutical composition for oral administration of edaravone and method of administering same (2025-11-25),

2. 12404247 - 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same (2025-09-02),

3. 12376781 - Brain wave analysis device, brain wave analysis system, and brain wave analysis program (2025-08-05),

4. 12338265 - Crosslinked artificial nucleic acid ALNA (2025-06-24),

5. 12320793 - Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing medicament containing 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient (2025-06-03),

6. 12310946 - Pharmaceutical composition for oral administration of edaravone and method of administering same (2025-05-27),

7. 12285409 - Edaravone suspension for oral administration (2025-04-29),

8. 12194025 - Pharmaceutical composition for oral administration of edaravone and method of administering same (2025-01-14),

9. 12102641 - Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof (2024-10-01),

10. 12077524 - Crystal of pyrrolidine compound (2024-09-03),

11. 11970463 - Compounds and their use (2024-04-30),

12. 11958812 - 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same (2024-04-16),

13. 11957660 - Edaravone suspension for oral administration (2024-04-16),

14. 11911366 - Pharmaceutical composition for oral administration of edaravone and method of administering same (2024-02-27),

15. 11890288 - Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof (2024-02-06),

Mitsubishi Tanabe Pharma Corporation is a global pharmaceutical company committed to the discovery, development, and delivery of innovative and effective pharmaceutical products. With a focus on neurological and autoimmune diseases, it strives to improve the quality of life for patients worldwide. Visit their website for more information.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

257 Patents

#64 in Osaka

#573 in Japan

#3,285 in the World

Mitsubishi Tanabe Pharma Corporation

Forward Citations = 645

737 inventors:

Takayuki Kawaguchi (17 out of 43 patents)

Mourad Saady (15 out of 44 patents)

Alistair Lochead (15 out of 75 patents)

4. Philippe Yaiche (15 out of 43 patents)

5. Toru Iijima (14 out of 15 patents)

Please report any incorrect information to support@idiyas.com

Loading…